Many small-molecule active pharmaceutical ingredients (APIs) exhibit low aqueous
solubility and benefit from generation of amorphous dispersions of the API and polymer to …

Methods were developed to systematically screen different polymer–surfactant combinations
for the purpose of enhancing amorphous active pharmaceutical ingredient (API) solubility …

Does the performance of an amorphous solid dispersion rely on having 100% amorphous
content? What specifications are appropriate for crystalline content within an amorphous …

Biorelevant dissolution testing has been widely used to better understand a drug or
formulation's behavior in the human gastrointestinal (GI) tract. The successful evaluation of …

In this study, a novel solvent-evaporation based technology to manufacture amorphous solid
dispersions (ASDs) called vacuum drum drying (VDD) was assessed in comparison to the …

The development of a weakly basic compound is often challenging due to changes in pH
that the drug experiences throughout the gastrointestinal tract. As the drug transitions from …

Application of amorphous solid dispersions (ASDs) is considered one of the most promising
approaches to increase the dissolution rate and extent of bioavailability of poorly water …

Amorphous solid dispersions (ASDs), where an active pharmaceutical ingredient (API) is
dissolved in a polymer, are a favored formulation technique to achieve sufficient …

The objective of the study was to develop an amorphous solid dispersion (ASD) for an
insoluble compound X by hot melt extrusion (HME) process. The focus was to identify …

Amorphous solid dispersion (ASD) is one of the formulation strategies for drugs displaying
low solubility and low oral bioavailability. In this study, high drug-loaded ASDs of drugs with …